Selection of hematopoietic stem cell transplantation for T-cell lymphoblastic lymphoma

Zhen Li; Binglei Zhang; Xinxin Fan; Ruirui Gui; Fengkuan Yu; Juan Wang; Yanli Zhang; Keshu Zhou; Yanyan Liu; Yufu Li; Jing Ding; Yongping Song; Jian Zhou

doi:10.3389/fonc.2023.1193237

Selection of hematopoietic stem cell transplantation for T-cell lymphoblastic lymphoma

Front Oncol. 2023 Jul 20:13:1193237. doi: 10.3389/fonc.2023.1193237. eCollection 2023.

Authors

Zhen Li¹, Binglei Zhang², Xinxin Fan¹, Ruirui Gui¹, Fengkuan Yu¹, Juan Wang¹, Yanli Zhang¹, Keshu Zhou¹, Yanyan Liu¹, Yufu Li¹, Jing Ding¹, Yongping Song², Jian Zhou¹

Affiliations

¹ Department of Hematology, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, Henan, China.
² Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.

Abstract

Background: Hematopoietic stem cell transplantation (HSCT) is an important treatment for T-cell lymphoblastic lymphoma/leukemia (T-LBL). To compare the efficacy and influencing factors of autologous hematopoietic stem cell transplantation (auto-HSCT) with those of allogeneic hematopoietic stem cell transplantation (allo-HSCT) from different donors for the treatment of T-cell lymphoblastic lymphoma/leukemia (T-LBL) and provide a basis for selection of appropriate transplant methods and donors.

Methods: To provide evidence of appropriate transplant methods for these patients, we retrospectively summarized the clinical characteristics of 75 T-LBL patients receiving HSCT at Henan Cancer Hospital between March 2012 and October 2021. Overall survival (OS), progression-free survival (PFS), cumulative incidence of relapse (CIR), non-relapse mortality (NRM), and related factors affecting efficacy were analyzed.

Results: The 3-year CIR (39.9% vs 31.1%, P=0.745), 3-year PFS (60.1% vs 49.6%, P=0.434), and 3-year OS (62.8% vs 53.0%, P=0.450) were not significantly different between the auto-HSCT and allo-HSCT groups. However, the 3-year NRM was significantly higher in the allo-HSCT group (0% vs 27.2%, P=0.033). Multivariate analysis showed that the first complete remission (CR1) after HSCT was an independent influencing factor of higher OS (HR=2.498, P=0.029) and PFS (HR=2.576, P=0.016). The absence of mediastinal invasion in patients receiving HSCT was an independent influencing factor of better PFS (HR=2.977, P=0.029) and lower CIR (HR=4.040, P=0.027). With respect to the impact of donor source, the NRM in the unrelated donor (URD) and haploid donor (HPD) groups was significantly higher than that in the auto-HSCT group (P=0.021 and P=0.003, respectively), while there was no significant difference between matched sibling donors (MSD) and auto-HSCT. Compared with the MSD-HSCT group, the auto-HSCT group showed an increasing trend in 3-year CIR (39.9 ± 11.1% vs 32.6 ± 11.2%, P=0.697) and a lower trend in 3-year OS (62.8 ± 11.4% vs 64.4 ± 12.2%, P=0.929).

Conclusions: HSCT is an effective consolidation treatment option for patients with T-LBL without mediastinal invasion and with CR1 before transplantation. For CR1 patients, auto-HSCT and MSD-HSCT are effective modalities for improving survival. In non-CR1 patients without an MSD, matched unrelated donors and haploidentical donor transplantations are the best treatment options to reduce relapse and improve prognosis.

Keywords: T-cell; allo-HSCT; auto-HSCT; hematopoietic stem cell transplantation; lymphoblastic lymphoma.